Financial Data
TSHA Financial Data
Revenue · Earnings · Margins · Balance Sheet · Cash Flow
TSHATaysha Gene Therapies, Inc.
Healthcare / Biotechnology
Low Priority
In Line With Peers
Latest quote
- Momentum32
- Value—
- Quality37
- Risk resilience37
- Sentiment—
Financial Data Overview
Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.
Quarterly Financial Statements
Updated Nov 16, 2026.
| Metric | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $5.49M | $0 | $1.99M | $2.3M | $2.02M |
| Gross Profit | $0 | $0 | -$295K | $5.19M | -$286K | $1.99M | $2.3M | $2.02M |
| Operating Income | -$41.87M | -$47.35M | -$43.49M | -$28.3M | -$34.02M | -$26.75M | -$21.42M | -$19.93M |
| Net Income | -$39.13M | -$46.64M | -$42.41M | -$27.85M | -$32.73M | -$26.88M | -$21.53M | -$18.79M |
| EPS | -$0.1 | -$0.13 | -$0.12 | -$0.08 | -$0.09 | -$0.09 | -$0.08 | -$0.09 |
| Metric | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$32.91M | -$40.43M | -$40.88M | -$26.72M | -$24.17M | -$20.18M | -$22.02M | -$18.31M |
| Capital Expenditure | -$443K | $1K | -$3.02M | -$250K | -$108K | -$2K | -$378K | $2K |
| Free Cash Flow | -$33.36M | -$40.42M | -$43.9M | -$26.97M | -$24.27M | -$20.18M | -$22.4M | -$18.31M |
| Net Cash Provided By Operating Activities | -$32.91M | -$40.43M | -$40.88M | -$26.72M | -$24.17M | -$20.18M | -$22.02M | -$18.31M |
| Metric | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $435.03M | $470.43M | $300.35M | $343.32M | $316.55M | $333.33M | $138.36M | $160.36M |
| Total Debt | $54.59M | $55.55M | $17.77M | $18.17M | $69.08M | $59.6M | $61.35M | $63.18M |
| Cash And Cash Equivalents | $422.83M | $455.41M | $276.58M | $319.77M | $297.34M | $312.76M | $116.59M | $139.04M |
| Total Liabilities | $78.06M | $83.17M | $88.41M | $96.38M | $97.57M | $84.6M | $83.3M | $88.84M |
| Total Stockholders Equity | $356.97M | $387.27M | $211.94M | $246.94M | $218.99M | $248.73M | $55.06M | $71.53M |
| Metric | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| P/E ratio | — | — | — | — | — | — | — | — |
| P/B ratio | 4.66 | 6.37 | 12.07 | 5.9 | 6.89 | 3.49 | 12.52 | 4.64 |
| P/S ratio | 303.56 | — | — | — | — | — | — | — |
| Debt To Equity | 0.15 | 0.14 | 0.08 | 0.07 | 0.32 | 0.24 | 1.11 | 0.88 |
| Free Cash Flow Yield | -8.69% | -5.50% | -4.51% | -6.44% | -5.64% | -9.52% | -12.19% | -24.58% |
| Metric | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| P/E ratio | — | — | — | — | — | — | — | — |
| P/B ratio | 4.66 | 6.37 | 12.07 | 5.9 | 6.89 | 3.49 | 12.52 | 4.64 |
| P/S ratio | 303.56 | — | — | — | — | — | — | — |
| Return On Equity | -43.71% | -38.64% | -61.28% | -44.14% | -45.63% | -37.28% | -157.59% | -124.85% |
| Debt To Equity | 0.15 | 0.14 | 0.08 | 0.07 | 0.32 | 0.24 | 1.11 | 0.88 |
Current Stock Metrics
Current fundamental, technical, and risk readings in one place.
| Metric | Value |
|---|---|
| Pe | -9.53x |
| Pb | 4.66x |
| EPS Growth Yoy | -7.99% |
| Gross Margin | 89.17% |
| Operating Margin | -2935.41% |
| ROE | -51.87% |
| ROIC | -38.96% |
| Debt To Equity | 0.15 |
| FCF Yield | -10.86% |
As of Nov 13, 2026
| Metric | Value |
|---|---|
| Close | $4.10 |
| Volume | 2.47M |
| RSI (14) | 44.68 |
| MACD | -0.06 |
| MACD signal | -0.1 |
| MACD histogram | 0.04 |
| ADX (14) | 15.07 |
| SMA (50) | $4.49 |
| SMA (200) | $5.30 |
| ATR (14) | $0.29 |
| Historical volatility (annualized) | 61.47% |
| Volume (20-day average) | 3.46M |
As of Nov 13, 2026
| Metric | Value |
|---|---|
| Resilience score | 37/100 |
| Beta | 1.73 |
| Annual volatility | 70.69% |
| Max Drawdown | -49.71% |
| Sharpe Ratio | 0.32 |
| VaR (95%, 1-day) | -6.50% |
As of Nov 13, 2026
Detailed Metrics
Additional measures remain available here while the decision pages stay focused.
No additional fundamental metrics are available.
No additional technical indicators are available.
No additional risk measures are available.
Related Links
TSHA Financial Data FAQ
What is Taysha Gene Therapies, Inc.'s revenue?
Taysha Gene Therapies, Inc.'s revenue is one of the core financial data points for TSHA. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.
Is Taysha Gene Therapies, Inc.'s revenue growing?
Revenue growth shows whether Taysha Gene Therapies, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.
What is TSHA's EPS?
TSHA's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.
What is Taysha Gene Therapies, Inc.'s net income?
Taysha Gene Therapies, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.
How much free cash flow does Taysha Gene Therapies, Inc. generate?
Free cash flow shows how much cash Taysha Gene Therapies, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.
How much cash and debt does Taysha Gene Therapies, Inc. have?
Cash and debt help frame TSHA's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.